Previous 10 | Next 10 |
2023-08-07 12:01:16 ET Shares of Mesoblast (NASDAQ: MESO) were down by more than 15% as of 11:45 a.m. ET on Monday, just days after the healthcare stock plunged more than 61% on bad news regarding one of its lead therapy candidates. Mesoblast is a pharmaceutical comp...
2023-08-07 10:15:28 ET Gainers: Poseida Therapeutics ( PSTX ) +33% . Tabula Rasa HealthCare ( TRHC ) +32% . Mallinckrodt plc ( MNK ) +17% . Assertio Holdings ( ASRT ) +18% . Palatin Technologies ( PTN ) +16% . Losers: Sag...
2023-08-07 08:21:42 ET Sage Therapeutics ( SAGE ) -47% after Q2 earning release . Yellow Corporation ( YELL ) -43% files for bankruptcy after prolonged labor row . Apellis Pharmaceuticals ( APLS ) -15% . ADTRAN Holdings ( ADTN ) -14% aft...
2023-08-04 14:46:32 ET Shares of Mesoblast (NASDAQ: MESO) were down more than 61% as of 2:15 p.m. on Friday. The pharmaceutical stock is down more than 54% so far this year. Mesoblast focuses on allogeneic cellular medicines to treat inflammatory diseases. On Friday, the com...
2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...
2023-08-04 09:31:23 ET More on Mesoblast Mesoblast: PDUFA In Less Than 2 Weeks Mesoblast stock surges ~10% on getting FDA review of graft versus host disease therapy Mesoblast reports operational and financial highlights for Q3 Seeking Alpha’s Quant Ra...
2023-08-04 08:35:01 ET Mesoblast Limited ( MESO ) -61% on receiving complete response from USFDA . Assertio Holdings ASRT -47% after Q2 earning release . ContextLogic WISH -22% after Q2 earning release . MIRA Pharmaceuticals ( MIRA ) -21% . ...
2023-08-04 07:30:56 ET More on Mesoblast Mesoblast: PDUFA In Less Than 2 Weeks Mesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18M Mesoblast stock surges ~10% on getting FDA review of graft versus host disease therapy New medical ...
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the US Food and Drug Administration (FDA) has provided a complete response to its Biologics License Application (BLA...
NEW YORK, July 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended June 30, 2023. Activities Report Cash balance at the end o...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...